

MAY 2010 DUR BOARD MEETING MINUTES

Date: May 26, 2010

Members Present: Eichler, Putsch, Brown, Burton, Sargent, Nagy, Crichton

Others Present: Roger Citron (Medicaid), Kathy Novak (First Health), Lisa Wilkinson and Marcella Barnhill (Drug PA/CM unit), and various members of the public and representatives of drug manufacturers.

PDL Review:

The Board made the following recommendations to the Department:

The Department proposes no changes to the following classes and all available chemical entities are preferred :

- MACROLIDES
- TOPICAL IMMUNOMODULATORS
- HEPATITIS C AGENTS
- IMMUNOSUPPRESSANTS

The Board agreed with the Department's proposal

The Department proposes no changes to the Formulary Committee's clinical recommendations within the following classes unless manufacturers submit **NEW** information:

- HERPETIC ANTIVIRALS
- 2nd GENERATION CEPHALOSPORINS
- 3rd GENERATION CEPHALOSPORINS
- 2nd GENERATION QUINOLONES
- 3rd GENERATION QUINOLONES
- BISPHOSPHONATES
- NASAL CALCITONINS
- LEUKOTRIENE MODIFIERS
- INHALED CORTICOSTEROIDS
- SABA INHALERS & NEBS
- LABA INHALERS & NEBS
- LABA COMBOS
- ANTIEMETICS

The Board agreed with the Department's proposal

The Department reviewed the following classes as **NEW** information is known to exist:

- INHALED ANTICHOLINERGICS~Spiriva
- PLATELET INHIBITORS-Effient
- INJECTABLE ANTICOAGULANTS
- SKELATAL MUSCLE RELAXANTS~NEW*
- ULCERATIVE COLITIS~NEW*
- NASAL ANTIHISTAMINE~Patanase
- IMMUNOMODULATORS~Stelara, Actrema
- ONCHOMYCOSIS ANTIFUNGALS~Terbinex
- TOPICAL RETINOIDS~NEW*
- TOPICAL ANTIBIOTICS~NEW*

The Board made the following recommendations:

Inhaled Anticholenergics:

Must have Ipratropium; May add Spiriva

Platelet Inhibitors:

Must have aspirin and Aggrenox; Plavix and Effient have a class effect and must have at least one.

Injectable Anticoagulants:

Therapeutic alternatives; Must have one LMWH and May add Arixtra

Skeletal Muscle Relaxants: New category

Carisoprodol products have been removed from this category. The Board has clinical edits in place on these products.

Must have baclofen; Other agents are therapeutic alternatives.

*Patients already on therapy will be *grandfathered* on current treatment

Ulcerative Colitis: New category

Must have 1 suppository and 1 enema; Must have 1 pro-drug and 1 delayed release product

*Patients already on therapy will be *grandfathered* on current treatment

Nasal Antihistamines:

Class effect

Immunomodulators:

Do Not add Kineret; Must have at least 1 of others, class effect.

Antifungals-Onchomycosis:

Must have Terbinafine, May add Sporanox, and griseofulvin

Topical Retinoids: New category

Must have adapalene; may have others

*Patients already on therapy will be *grandfathered* on current treatment

Topical Antibiotics: New category

Must have a mupirocin product; may have Altobax.

No grandfathering will be in effect in this class.

Next and final PDL meeting will be held at the Great Northern at 1PM on Wednesday June 30, 2010. Mark verified the meeting date with those present.
Meeting adjourned at 2:20 PM.